SUNNYVALE, Calif., May 14 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, today announced it has expanded its executive team to help prepare for commercialization of its first product and grow the company. W. David Henner, MD, PhD, joins the company as chief medical officer and David Craford will serve as vice president, commercial operations.
Dr. Henner is responsible for providing clinical and medical leadership for the company’s clinical pipeline, thought leader development, collaborations and clinical study design. He comes to Pathwork Diagnostics from Novacea, Inc., a biopharmaceutical company, where he served as vice president of oncology. In addition to industry leadership in product and clinical development, his experience includes scientific and clinical research in oncology and pharmacology, and clinical practice in oncology. Dr. Henner received his MD and PhD from the University of Pennsylvania and his MBA from the University of Oregon. He completed his residency at the University of Chicago Hospital and his clinical fellowship in medical oncology at Harvard Medical School and Dana-Farber Cancer Institute.
Mr. Craford is charged with leading Pathwork Diagnostics’ overall marketing, sales and customer support strategies and operations. He has 20 years of experience in sales, marketing and business development in the life sciences industry. Most recently he served as vice president of business development at Affymetrix, where during his tenure he successfully managed corporate partnerships, brought complex new products to market and helped establish their market leadership. Mr. Craford received his BA in biochemistry and cell biology from the University of California San Diego and his MBA at University of California Berkeley’s Haas School of Business.
“I am pleased to add seasoned executives of the caliber of Dr. Henner and Mr. Craford to our executive leadership team,” said Deborah J. Neff, president and chief executive officer of Pathwork Diagnostics. “Dr. Henner brings outstanding scientific, clinical and industry experience to the company and will be key to establishing the clinical credentials of the Pathwork(TM) Tissue of Origin Test and to building our clinical product pipeline. Mr. Craford’s outstanding track record for building new markets and creating sales strategies will also be highly valuable as we create a market-leading position for the company.”
Pathwork Diagnostics, based in Sunnyvale, California, develops and delivers genomics-based diagnostics that advance cancer care. The company solves unmet needs in oncology by combining microarray technology with proprietary informatics to provide clinically actionable information in a robust and reproducible manner. The company’s first test -- the Pathwork(TM) Tissue of Origin Test -- is under FDA review and is expected to aid in the diagnosis of patients with uncertain primary cancers, in which a tumor’s origin cannot be readily identified. This approach could potentially enable oncologists to begin standard-of-care, tissue-directed treatment more promptly for patients.
Pathwork Diagnostics
CONTACT: Tracy Morris of Pathwork Diagnostics, +1-650-473-1272, ortracy@morrismarcom.com
Web site: http://www.pathworkdx.com//
